Temasek Holdings (Private) Ltd

recently stated that they own a 13.1% stake in Amyris, Inc. (NASDAQ:AMRS) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Tuesday, October 3rd. The investor owns 5,192,571 shares of the stock valued at approximately $17,031,633. The reporting parties listed on the disclosure included Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd, Cairnhill Investments (Mauritius) Pte Ltd and Maxwell (Mauritius) Pte Ltd. The filing is available through Edgar at this hyperlink.

Separately, Bank of New York Mellon Corp lifted its holdings in shares of Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after buying an additional 4,603 shares during the period. 19.79% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at

Amyris, Inc. (NASDAQ AMRS) traded up 0.457% during trading on Tuesday, hitting $3.295. The stock had a trading volume of 78,871 shares. The firm’s market cap is $123.91 million. Amyris, Inc. has a 12-month low of $0.21 and a 12-month high of $18.15. The stock’s 50 day moving average price is $2.87 and its 200 day moving average price is $4.54.

Amyris (NASDAQ:AMRS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.35). The business had revenue of $25.68 million for the quarter, compared to the consensus estimate of $23.68 million. During the same period in the prior year, the firm posted ($0.06) EPS. The company’s revenue was up 167.5% compared to the same quarter last year. On average, analysts anticipate that Amyris, Inc. will post ($3.42) EPS for the current fiscal year.

AMRS has been the subject of several research reports. Zacks Investment Research raised shares of Amyris from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Cowen and Company set a $4.00 target price on Amyris and gave the stock a “hold” rating in a research note on Thursday, August 17th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Amyris in a report on Tuesday, September 26th. Finally, ValuEngine upgraded shares of Amyris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $26.33.

Amyris Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.